TRV-734 is under clinical development by Trevena and currently in Phase II for Opium Withdrawal Syndrome. According to GlobalData, Phase II drugs for Opium Withdrawal Syndrome have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how TRV-734’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TRV-734 overview
TRV-734 is under development for the treatment of opium withdrawal syndrome. It is a small molecule administered orally. TRV-734 is an oral follow on program to the intravenous TRV-130. It targets mu-opioid receptor to optimize analgesia. The drug candidate is a new chemical entity and it is developed based on Advanced Biased Ligand Explorer (ABLE) platform. It was also under development for moderate to severe acute and chronic pain.
Trevena overview
Trevena is a biotechnology company. It discovers and develops G-protein coupled receptor targeted medicines. The company provides products such as RV045, TRV734 and TRV250. Its TRV045 is an oral drug used for the treatment of acute and chronic neuropathic pain secondary to diabetic peripheral neuropathy. Trevena’s TRV734 is also an oral drug which is used in medication- assisted therapy for the treatment of opioid use disorder. The company’s GPCR is associated with beneficial versus adverse biological effects. Its TRV250 is an oral delta opioid biased ligand for treatment of refactory migraine. Trevena is headquartered in Chesterbrook, Pennsylvania, the US.
For a complete picture of TRV-734’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
